Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Anheuser-Busch Inbev SA (BUD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Anheuser-Busch Inbev SATrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Anheuser-Busch Inbev SA vs State Street SPDR S&P Biotech ETF — how do they compare? Anheuser-Busch Inbev SA trades at $79.28 (market cap $159.01B), while State Street SPDR S&P Biotech ETF trades at $158.93. The key difference: Anheuser-Busch Inbev SA pays a 1.67% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Anheuser-Busch Inbev SA nearer its low. Which is the better fit depends on your goals.

BUDXBI
Market Cap
$159.01B
Sector
Consumer StaplesBroad Market / Factor
52-Week High
$86.48$164.28
52-Week Low
$57.93$86.92
Enterprise Value
$223.42B
Dividend Yield
1.67%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Anheuser-Busch Inbev SA

BUD trades at $79.3, down 4.56% on the day, with a bearish technical signal from moving averages and oscillators. Fundamentally, the company reported Q2 2026 EPS of $1.21, beating estimates, and maintains strong cash flow with $14.88B from operations in 2025. Revenue for 2025 was $59.32B, with net income margin improving to 11.52%. Recent news includes mixed institutional activity and Q2 earnings coverage highlighting volume growth and premium brand strength.

The outlook is supported by analyst consensus with a $90.17 price target and 57.78% buy ratings, but risks include recent shareholder share sales and competitive pressures. Earnings growth and deleveraging trends provide upside, while technical weakness near support at $79 requires monitoring for stability.

State Street SPDR S&P Biotech ETF

XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.

Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.

Returns comparison

Trailing returns across standard periods

About Anheuser-Busch Inbev SA

Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.

Read more on BUD

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI